

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	76,141	99.9%	58,824	99.9%	8,413	99.8%	7,627	99.9%	267	100.0%	7,484	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	64,696	84.8%	49,379	83.8%	7,385	87.6%	6,930	90.8%	234	87.6%	6,433	85.8%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,557	8.6%	4,913	8.3%	774	9.2%	762	10.0%	21	7.9%	653	8.7%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,243	6.9%	4,125	7.0%	498	5.9%	540	7.1%	22	8.2%	449	6.0%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	22,102	29.0%	17,159	29.1%	2,481	29.4%	2,071	27.1%	86	32.2%	2,161	28.8%
Comedocarcinoma <i>in situ</i> (8501/2)	6,258	8.2%	4,762	8.1%	680	8.1%	723	9.5%	34	12.7%	588	7.8%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,171	1.5%	801	1.4%	205	2.4%	142	1.9%	-	-	125	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	268	0.4%	164	0.3%	43	0.5%	61	0.8%	-	-	31	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,272	1.7%	995	1.7%	163	1.9%	94	1.2%	-	-	137	1.8%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	21,637	28.4%	16,326	27.7%	2,531	30.0%	2,495	32.7%	64	24.0%	2,274	30.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,761	11.5%	7,323	12.4%	733	8.7%	462	6.1%	29	10.9%	817	10.9%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,743	11.5%	7,309	12.4%	730	8.7%	462	6.1%	28	10.5%	816	10.9%
Lobular CIS ^f with other CIS ^f (8524/2)	18	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,166	2.8%	1,739	3.0%	231	2.7%	169	2.2%	-	-	185	2.5%
Other adenocarcinomas ^g	512	0.7%	380	0.6%	63	0.7%	64	0.8%	-	-	49	0.7%
Other <i>in situ</i> histologies ^h	111	0.1%	84	0.1%	-	-	-	-	-	-	-	-
Total	76,252	100.0%	58,908	100.0%	8,428	100.0%	7,632	100.0%	267	100.0%	7,495	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.